The search strategy targeted studies involving GLP-1 receptor agonists (e.g., exenatide, liraglutide, dulaglutide, lixisenatide, benaglutide, loxenatide, semaglutide) and multi-target receptor agonists (e.g., tirzepatide), focusing on gastrointestinal adverse events (e.g., nausea, vomiting, diarrhea, constipation, dyspepsia, and reduced appetite) in patients with type 2 diabetes mellitus (T2DM) (Supplementary Material)
It acts like a cellular shield, neutralizing these molecules before they can cause damage
doi: 10.1155/2020/3921074 14
Rushing this process offers no benefit and carries real risk of severe side effects that could compromise the entire protocol
Differential diagnosis of malignant diseases is quite important because of the lethality of the disease
Bibcode:2017Natur.547..453V